Generation of a Mouse Model of Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System through Combined Deletion of Snf5 and p53
- 1 November 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (21) , 4629-4639
Abstract
Malignant rhabdoid tumors arise in several anatomic locations and are associated with poor outcomes. In the brain, these tumors are known as atypical teratoid/rhabdoid tumors (AT/RT). While genetically engineered models for malignant rhabdoid tumors exist, none of them recapitulate AT/RT, for which preclinical models remain lacking. In the majority of AT/RT, LOH occurs at the genetic locus SNF5 (Ini1/BAF47/Smarcb1), which functions as a subunit of the SWI/SNF chromatin-remodeling complex and a tumor suppressor in familial and sporadic malignant rhabdoid tumors. Therefore, we generated mice in which Snf5 was ablated specifically in nestin-positive and/or glial fibrillary acid protein (GFAP)-positive progenitor cells of the developing central nervous system (CNS). Snf5 ablation in nestin-positive cells resulted in early lethality that could not be rescued by loss of p53. However, Snf5 ablation in GFAP-positive cells caused a neurodegenerative phenotype exacerbated by p53 loss. Notably, these double mutants exhibited AT/RT development, associated with an earlier failure in granule neuron migration in the cerebellum, reduced neuronal projections in the hippocampus, degeneration of the corpus callosum, and ataxia and seizures. Gene expression analysis confirmed that the tumors that arose in Snf5/p53 mutant mice were distinct from other neural tumors and most closely resembled human AT/RT. Our findings uncover a novel role for Snf5 in oligodendrocyte generation and survival, and they offer evidence of the first genetically engineered mouse model for AT/RT in the CNS. Cancer Res; 75(21); 4629–39. ©2015 AACR.Keywords
All Related Versions
This publication has 51 references indexed in Scilit:
- A remarkably simple genome underlies highly malignant pediatric rhabdoid cancersJournal of Clinical Investigation, 2012
- p16INK4Aand p14ARFTumor Suppressor Pathways Are Deregulated in Malignant Rhabdoid TumorsJournal of Neuropathology & Experimental Neurology, 2011
- Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumorsPediatric Blood & Cancer, 2010
- Interictal EEG spikes identify the region of electrographic seizure onset in some, but not all, pediatric epilepsy patientsEpilepsia, 2010
- Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling ComplexCancer Research, 2009
- Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5+/−;p53+/− miceMolecular Carcinogenesis, 2009
- Targeted loss of Arx results in a developmental epilepsy mouse model and recapitulates the human phenotype in heterozygous femalesBrain, 2009
- Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosisClinical Genetics, 2008
- Germline Mutation of INI1/SMARCB1 in Familial SchwannomatosisThe American Journal of Human Genetics, 2007
- Pathological and Molecular Progression of Astrocytomas in a GFAP:12V-Ha-Ras Mouse Astrocytoma ModelThe American Journal of Pathology, 2005